We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+12.1%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.3B
AUM Growth
+$892M
Cap. Flow
+$30.9M
Cap. Flow %
0.25%
Top 10 Hldgs %
85.9%
Holding
130
New
9
Increased
23
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$33.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$17.1M
3
ONC
BeOne Medicines Ltd
ONC
+$16.8M
4
SAGE
Sage Therapeutics
SAGE
+$15.5M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.5M

Top Sells

Rank Stock Value
1
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$22.1M
2
AKAO
Achaogen Inc
AKAO
+$17.5M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.3M
4
BLUE
bluebird bio
BLUE
+$6.47M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 99.02%
2 Miscellaneous 0.97%
3 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HALO icon
26
Halozyme
HALO
$12.3B
$27.5M 0.22%
1,581,424
– –
CERS icon
27
Cerus
CERS
$514M
$26.6M 0.22%
9,745,209
-496,734
-5% -$1.22M
MRTX
28
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$26.5M 0.22%
2,269,198
– –
LKFT
29
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.76B
$26.4M 0.21%
259,894
– –
NTLA icon
30
Intellia Therapeutics
NTLA
$1.66B
$26.4M 0.21%
1,062,120
– –
SAGE
31
DELISTED
Sage Therapeutics
SAGE
$25.3M 0.2%
405,485
+197,157
+95% +$15.5M
CBAY
32
DELISTED
Cymabay Therapeutics
CBAY
$24.1M 0.2%
2,991,775
+1,700,000
+132% +$11.5M
PGNX
33
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$23.2M 0.19%
3,150,808
– –
MRUS
34
DELISTED
Merus
MRUS
$23M 0.19%
1,160,014
– –
ACGN
35
DELISTED
Aceragen Inc
ACGN
$23M 0.19%
9,483
+11
+0.1% +$23K
NDRM
36
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$22.2M 0.18%
571,667
– –
INSM icon
37
Insmed
INSM
$28.3B
$21.8M 0.18%
700,000
+300,000
+75% +$5.71M
IMGN
38
DELISTED
Immunogen Inc
IMGN
$20.6M 0.17%
2,688,489
-326,864
-11% -$2.17M
XNCR icon
39
Xencor
XNCR
$1.81B
$20M 0.16%
872,072
– –
AIMT
40
DELISTED
Aimmune Therapeutics
AIMT
$16.7M 0.14%
673,908
– –
RXDX
41
DELISTED
Ignyta, Inc.
RXDX
$16M 0.13%
1,299,199
+403,199
+45% +$4.16M
MYOK
42
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$15.2M 0.12%
355,264
+255,264
+255% +$8.14M
AERI
43
DELISTED
Aerie Pharmaceuticals
AERI
$14.5M 0.12%
299,356
– –
FOMX
44
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$13.7M 0.11%
2,466,702
– –
CPRX
45
DELISTED
Catalyst Pharmaceutical
CPRX
$12.9M 0.1%
5,102,153
– –
ACOR
46
DELISTED
Acorda Therapeutics
ACOR
$12.3M 0.1%
+4,329
New +$11.4M
LUMO
47
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$10.3M 0.08%
111,919
+56,363
+101% +$4.32M
LGND icon
48
Ligand Pharmaceuticals
LGND
$5.67B
$9.99M 0.08%
117,638
– –
ITCI
49
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.61M 0.08%
609,166
– –
LOXO
50
DELISTED
Loxo Oncology, Inc
LOXO
$8.85M 0.07%
96,062
-42,250
-31% -$3.28M
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Baker Bros. Advisors held 130 positions worth $12.3B, up 7.8% from $11.4B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2017 filing shows 9 new, 23 increased, 9 reduced and 9 closed positions. Its largest new stake was Acorda Therapeutics: 4,329 shares worth $12.3M. The largest sale was SANGAMO THERAPEUTICS INC, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Technology.

  • Baker Bros. Advisors's largest Q3 2017 buy was Acorda Therapeutics: 4,329 shares worth $12.3M.
  • Baker Bros. Advisors added most to Array Biopharma Inc in Q3 2017, an estimated $33.7M increase.
  • Baker Bros. Advisors's biggest Q3 2017 reduction was SANGAMO THERAPEUTICS INC, cutting an estimated $22.1M.
  • Baker Bros. Advisors fully exited Zogenix, Inc. in Q3 2017, selling an estimated $2.69M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $12.3B portfolio in Q3 2017.
  • Baker Bros. Advisors opened 9 new positions and closed 9 in Q3 2017.
  • Baker Bros. Advisors's portfolio value rose 7.8% quarter-over-quarter to $12.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.